No abstract available.
Giant Cell Tumor of Bone* ; Giant Cell Tumors* ; Giant Cells*

The study was performed on 79 patients with the bone giant cell tumor in the center for trauma and orthopady in Hå ChÝ Minh during 12/1991 -12/1996. Results showed that: the disease occurred in ages of 10-70 in which mainly in ages of 20-40 (70.89%), female/male is 1.47. The X-ray lesion included merely osteoclast: 100%, osteoclast occurred in the epiphysis of long bone: 96,20%; osteocortical hypertrophy, image of alveolate 83.54%, clear limitation (70.89%), eccentric: 31.24%, condensed periosteum 8.86%, invasion into soft tissue: 35.44%, pathological bone fracture: 27.85%. Density of X-ray: grade I 30.38%, grade II: 34.18% and grade III: 35.44%, the correct diagnosis by X-ray 61.26%.
X-Rays ; Anatomy ; Giant Cell Tumor of Bone

BACKGROUND AND OBJECTIVES

Giant cell tumor of bone (GCTB) is a benign aggressive tumor primarily treated with surgery. Neoadjuvant treatment with denosumab or zoledronic acid is a common adjunct given to down-stage tumors and facilitate limb sparing surgery. This study sought to determine the characteristics, outcomes, and occurrence of complications following resection (RS) or extended curettage (EC) for GCTB of the lower extremities. Correlation of neoadjuvant therapy with the occurrence of complications was also investigated.

This is an analytical cross-sectional study of 30 patients diagnosed with GCTB of the lower extremity treated between 2015 to 2022 in a single tertiary hospital. Functional outcomes were determined using the 1993 version of the Musculoskeletal Tumor Society (MSTS) score. Mean follow-up for all patients was 2.6 years (SD 1.8). Twenty-two patients (73%) underwent resection, while eight (27%) patients underwent extended curettage. Of the 30 patients, 26 (87%) patients received neoadjuvant therapy, with 21 (81%) given denosumab and five (19%) given zoledronic acid.

Functional outcomes were excellent for 23 patients (77%), with no significant difference between RS and EC groups. Nine complications occurred in the RS group, including dehiscence (n=3), superficial infection (n=2), implant failure (n=1), nonunion (n=1), palsy (n=1), and implant irritation (n=1). Five complications occurred in the EC group, four of which were noted to be recurrences, with one case of deep infection. Recurrence was noted to be significantly higher (p=0.0004) in the EC group. Separate correlation analysis showed no significant difference in incidence of complications but found that duration of surgery was significantly longer (p=0.0001), and intraoperative blood loss was significantly higher (p=0.0072) in the RS group. No significant difference (p=0.78) was noted in complication rate between patients given denosumab versus zoledronic acid.

Functional outcomes of EC and RS appear to be comparable, including the incidence of complications. However, recurrence was noted to be significantly higher in EC. There appears to be no clear advantage between denosumab or zoledronic acid for GCTB. As a neoadjuvant medication and/or to control tumor progression, zoledronic acid may be the more economic option especially for patients in developing countries.

PURPOSE: To describe the MR characteristics of giant cell tumor of bone. MATERIALS AND METHODS: MR iraagings of 15 cases of pathologically proved giant cell tumor were retrospectively analyzed. Signal intensity and homogeneity, involvement of articular surface, low signal intensity rim around the tumor, cortical disruption and soft tissue involvement were evaluated. RESULTS:Tumor showed low signal intensity on T1 weighted images(93%), inhomogenous high signal on T2 or T2* weighted images(93%) and inhomogeneous enhancing pattern(88%). In 11 cases of giant cell tumor of long bones, all cases showed involvement of articular margin and 10 cases(90%) showed rim of low signal intensity between tumor and normal marrow. Disruption of cortical bone(25%) and soft tissue involevement(7%) were also demonstrated. CONCLUSION: We concluded that giant cell tumor showed characteristic MR findings could be helpful in making correct diagnosis.
Bone Marrow ; Diagnosis ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Retrospective Studies

Giant cell tumor of bone is an uncommon, primary neoplasm that occurs chiefly in the ends of the long bones. Giant cell tumor is rarely encountered in the skull, where it preferentially involves the sphenoid, ethmoid, and temporal bones. Radiographically, there are no characteristic findings which can be regarded as typical of a giant cell tumor. Therefore, the diagnosis must be made by biopsy. This tumor is characterized by benign histologic features, but it can be locally aggressive and can even metastasize. Complete surgical excision is the treatment of choice for giant cell tumor. We have experienced a case of giant cell tumor of the temporal bone which was removed with infratemporal fossa approach type B. So, we report with review of literatures.
Biopsy ; Diagnosis ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Skull ; Temporal Bone*

PURPOSE: To describe MR findings of recurred giant cell tumor of bone. MATERIALS AND METHODS: MR imagings of ten cases of pathologically proven recurrence of giant cell tumor were retrospectively analyzed. Location of recurrence, multiplicity of recurred tumor, signal intensity and homogeneity, pattern of gadolinium enhancement, soft tissue and articular surface involvement were evaluated. RESULTS: Tumors were located in peripheral portion of previous operation site(80%). Six cases recurred as multiple lesions. Tumor showed low signal intensity on T1 weighted images(100%), high signal intensity on T2 weighted images(100%) and inhomogeneous peripheral rim enhancing pattern(75%). Soft tissue and articular surface involvement were also demonstrated. CONCLUSION: We concluded that characteristic MR findings of recurred giant cell tumor could be helpful in early detection and precise evaluation of tumor recurrence.
Gadolinium ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Recurrence ; Retrospective Studies

Based on clinical, operative and pathological finding in twenty six cases of giant cell tumor, treated by curettage and bone graft in 14 and resection and bone graft in 5 buring 19 years, from 1958 to 1976, following results were obtained. Even in this study, according to others, giant cell tumors were mostly located around the knee in 16 cases. Following up results postoperatively, the overall recurrence rate of giant cell tumor was 38 percent. Especially in curettage and bone graft, it was recurred in 43 percent. Tumor located around the knee and vertebrae showed higher rate of recurrence than those in other sites. Four of the six patients who had an episode of recurrence recurred within the second years, and the other one in the third years after curettage and bone graft. All the two cases who had experienced a second recurrence were resulted in recurrence within second years after curettage and bone graft. Three of six patients treated by curettage and bone graft as secondary treatment had no recurrence.
Curettage ; Giant Cell Tumor of Bone ; Giant Cell Tumors ; Giant Cells ; Humans ; Knee ; Recurrence ; Spine ; Transplants

Giant cell tumor of bone is a locally aggressive benign neoplasm, which is composed of oval or plump, spindle-shaped mononuclear cells and uniformly distributed multinucleated giant cells. Bone or cartilage matrix production by the tumor cells is usually not seen. We present a pathologically proven case of giant cell tumor, arising in the acetabulum and pubic bone, with unusual cartilage matrix production. We also discuss the differential diagnosis from a chondroblastoma as well as a giant cell-rich osteosarcoma.
Acetabulum ; Cartilage* ; Chondroblastoma ; Diagnosis, Differential ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Osteosarcoma ; Pubic Bone

Giant cell tumor of bone, which occurs chiefly in the ends of the long bones and is composed of osteoclastic giant cells surrounded by mononuclear cells, is rare in the temporal bone. Giant cell tumor is pathologically benign but locally aggressive and can even metastasize. Complete surgical excision is the treatment of choice for giant cell tumor. We experienced a case of giant cell tumor in a 47 years old male patient. The cell tumor originated in the petrous and squamous portion of the temporal bone and destructed the surrounding tissues. The tumor was removed through subtotal temporal bone resection with modification. The surgical defect was reconstructed with temporal muscle rotation flap and split thickness skin graft. Thus, we report this case with a review of literature.
Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Humans ; Male ; Middle Aged ; Osteoclasts ; Skin ; Temporal Bone* ; Temporal Muscle ; Transplants

A giant cell tumor of bone is a benign bone tumor, but has very high local recurrence rate and, very rarely metastasizes to the lung or a distant area. We report a case of a 29-year-old male patient presenting with a metastatic giant cell tumor of the soft tissue of the chest wall, who underwent a total resection of the radius for recurrence of the giant cell tumor. The tumor was not related to any bony structure of the thorax. We resected the tumor with a wide surgical margin. No evidence of malignancy was seen in the frozen and permanent pathological report.
Adult ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Humans ; Lung ; Male ; Radius ; Recurrence ; Thoracic Wall* ; Thorax